PlainRecalls

Ino Therapeutics (dba Ikaria)

Compiled from official public sources by the publisher.

4 recalls on record · Latest: Feb 1, 2017

Subscribe to new Ino Therapeutics recalls (RSS)

Agency notice ledger

Federal filing book Ino Therapeutics LIGHT-BOOK · SINGLE-AGENCY

#2,967 of 14,151 · 4 notices · 0.004% archive

  • BOOK 4 notices
  • RANK #2,967 of 14,151
  • SHARE 0.004% archive
  • AGENCY FDA Devices (4)
  • CAT medical devices
  • CATS 1 category
  • LATEST Feb 1, 2017
  • PHOTO 1 Epic, LLC

Nearest notice-volume peer: 1 Epic, LLC (0 notice gap)

Ino Therapeutics (dba Ikaria) accounts for about 0.004% of the 104,423-notice archive on 4 distinct filings — a light share signal beside absolute volume. FDA · CPSC · USDA FSIS · NHTSA notice stamps for this firm. Read with this firm → · Dominant category → · Similar-volume firm →

Where Ino Therapeutics sits among 14,151 recalling firms

Ino Therapeutics (dba Ikaria) ranks 2,967th of 14,151 tracked firms by distinct recall-event count. Archive size reflects filing volume, not inherent product danger.

Ino Therapeutics vs all firms by recall-notice count

Where this firm's archive sits among every tracked recalling manufacturer

4 2967th of 14151 higher than 10,859 of 14,151 firms

Firms, banded by distinct federal recall-event inventory

Each bar is a band; taller bars hold more firms. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source FDA · CPSC · USDA FSIS · NHTSA federal recall filings · 2026-09-13

Ino Therapeutics in the notice-volume neighbourhood

Distinct federal recall events among this firm and nearest nationwide peers

notices

What this shows Ino Therapeutics (dba Ikaria) holds about 0.004% of archive notices alongside 4 distinct filings.

Source FDA · CPSC · USDA FSIS · NHTSA filings aggregated by PlainRecalls As of September 2026
FDA Devices Moderate Feb 1, 2017

Mallinckrodt Pharmaceuticals INOmax DSIR Plus delivery system. Model 10007. Delivers INOMAX (nitric oxide for inhalation). The INOmax DSIR uses a dual-channel design to ensure the safe delivery of INOMAX. The first channel has the delivery CPU, the flow controller and the injector module to ensure the accurate delivery of NO. The second channel is the monitoring system, which includes a separate monitor CPU, the gas cells (NO, NO2, and 02 cells) and the user interface including the disp
FDA Devices Moderate Mar 11, 2015

Ikaria, INOmax DSIR (Delivery System), Model 10007. Nitric oxide delivery system for use with ventilators.
FDA Devices Moderate Dec 17, 2014

INOMAX DSIR Nitric Oxide delivery system, Model 10007, software version 3.1.0., delivers INOMAX (nitric oxide for inhalation) therapy gas and provides continuous monitoring of inspired O2, NO2, and NO, and comprehensive alarm systems. The primary clinical settings are Neonatal Intensive Care Units (NICU) and to transport of neonates.
FDA Devices Moderate May 14, 2014

INOmax DSIR, model 10007, Nitric Oxide Delivery System, with Software version 3.0.0. The INOmax DS delivery system delivers INOMAX (nitric oxide for inhalation) therapy gas and provides continuous monitoring of inspired O2, NO2, and NO, and a comprehensive alarm system. The primary targeted clinical setting is the Neonatal Intensive Care Unit (NICU) and secondary targeted clinical setting is the transport of neonates.

Ino Therapeutics is a small archive contributor

Drug and device firms outside this manufacturer and state, matched by notice volume and category footprint.

Similar recall count

Nearest multi-notice firms by distinct-event totals (4 here).

1 Epic, LLC 4 3rd Day Beverages LLC 4 A.p. Deauville, LLC 4 Aaa Pharmaceutical, Inc. 4 Aap Implantate Ag 4

Similar medical devices volume

Nearest multi-notice firms in the same narrow category lane.

Aap Implantate Ag 4 Ab Sciex, LLC 4 Accelerate Diagnostics Inc 4 Accord Media, LLC 4

Frequently Asked Questions

How many federal recall notices name Ino Therapeutics? ▼
PlainRecalls indexes 4 distinct federal recall events naming Ino Therapeutics (dba Ikaria), aggregated from FDA, CPSC, USDA FSIS, and NHTSA filings (archive as of September 2026). That count is an issuance inventory, not a hazard score.
Where does Ino Therapeutics sit among other recalling firms? ▼
Ino Therapeutics (dba Ikaria) ranks #2,967 of 14,151 by distinct recall-event count among 14,151 firms in this archive (77th percentile of firms with fewer notices). Rank tracks filing frequency, not product danger.
Which agency issues most of Ino Therapeutics's notices? ▼
FDA Devices accounts for 4 of this firm's 4 indexed notices.
What product category dominates Ino Therapeutics's filing book? ▼
Filings for Ino Therapeutics (dba Ikaria) span 1 product category, led by medical devices. Browse that category archive for peer firms and related notices.
Is a higher notice count more dangerous? ▼
No. Archive size reflects how often federal agencies publish recalls naming the firm — reporting volume, coverage, and product range all move the number. Always verify the individual notice with the issuing agency before acting on a specific product.
Ino Therapeutics (dba Ikaria): 4 federal recall notices aggregated from FDA, CPSC, USDA FSIS, and NHTSA filings (lead agency FDA Devices). Verify individual notices with FDA directly before acting on a specific recall.

Firm-level totals aggregate distinct federal recall events naming Ino Therapeutics (dba Ikaria); individual notices remain authoritative on each linked recall page.

Methodology · Corrections · FDA · CPSC · USDA FSIS · NHTSA · Archive as of September 2026